Two recent studies have reported that COVID boosters can increase the humoral response in MS patients during treatment with ocrelizumab or fingolimod. A number of studies have reported that these disease-modifying therapies (DMT) are associated with a blunted humoral response to COVID vaccination (Achiron et al. Ther Adv Neurol Disord 2021;14:17562864211012835. Gallo et al. Neurol Sci 2021;42:3523-3526). Read More
Latest News
2022 – the year in review
November 29, 2022Take the survey: Looking back on 2022
In 2022, the most noteworthy event was the announcement that the COVID-19 pandemic was over. That was reassuring news, although there have been 316 million reported cases this year, about 50% of all COVID cases to date. Canada saw an average of 48 COVID-related deaths per day post-pandemic. Read More
CLINICAL CASES IN MS – A STABLE PATIENT WITH RISING JCV INDEX
November 17, 2022Click here to watch Dr. Daniel Selchen discuss the case and the responses to the survey.
Craig is a 36-year-old salesperson with no prior medical history. In 2012, he presented with optic neuritis. Six months later he experienced a myelopathic episode. MRI-brain and -C-spine revealed a moderate disease burden of seven T2 lesions and one Gd+ lesion. He was started on interferon-beta-1a s.c. in 2013. Read More
SPMS pathogenesis and treatment
November 14, 2022ECTRIMS Special Report
Secondary-progressive multiple sclerosis (SPMS) was an area of special interest at the recent European Committee for Treatment and Research in MS (ECTRIMS) annual meeting, held October 26-28 in Amsterdam, The Netherlands. Read More